Company: AGIO
Filing Date: 2025-02-13
Form Type: 10-K
Source: 0001439222-25-000009
Chunk: 13

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-02-13
Form: 10-K
Item: Item 16
Chunk 13
---
 — — 42,847 Common stock issued under stock incentive plan and ESPP1,211,207 1 14,441 — — — — 14,442 Balance at December 31, 202473,372,696 $73 $2,493,811 $(1,518)$(148,924)(16,216,411)$(802,486)$1,540,956 

See accompanying Notes to Consolidated Financial Statements.

F-7

Agios Pharmaceuticals, Inc.

Consolidated Statements of Cash Flows

(In thousands) Years Ended December 31:202420232022Operating activitiesNet income (loss)$673,725 $(352,088)$(231,801)Adjustments to reconcile net income (loss) to net cash used in operating activities:Depreciation and amortization5,653 6,623 8,564 Stock-based compensation expense42,847 44,766 49,296 Net accretion of discount on marketable securities(14,486)(5,051)(1,198)Gain on sale of contingent payments(889,136)— (127,853)Loss (gain) on disposal of property and equipment(39)553 (48)Non-cash operating lease expense11,530 10,720 9,995 Expense associated with license agreement— 17,500 — Realized gain on investments(167)(28)— Milestone payment from gain on sale of oncology business(200,000)— — Changes in operating assets and liabilities:Accounts receivable, net(1,299)(604)(2,206)Inventory(8,540)(10,584)(8,492)Other receivables— — 447 Prepaid expenses and other current and non-current assets(5,811)3,833 (176)Accounts payable6,601 (8,733)3,436 Accrued expenses3,694 12,817 (1,617)Income taxes payable871 — — Operating lease liabilities(15,008)(13,663)(10,828)Other liabilities(276)(2,123)3,003 Net cash used in operating activities(389,841)(296,062)(309,478)Investing activitiesPurchases of marketable securities(1,542,433)(417,930)(1,030,781)Proceed